Objective: To determine the application value of quantitative analysis of contrast-enhanced ultrasonography (CEUS) in evaluation of early response of colorectal cancer liver metastasis to bevacizumab plus cytotoxic chemotherapy or cytotoxic chemotherapy alone. Methods: Twenty-eight patients with colorectal cancer liver metastasis were designated to bevacizumab plus mFOLFOX6 treatment group and mFOLFOX6 alone treatment group, with 14 cases in each group. Conventional ultrasound and CEUS were performed 1d prior to the first four administrations of chemotherapy, and quantitative parameters of liver metastases were recorded by using contrast dynamic software. Based on the final results assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), the differences in percentage change of the quantitative parameters of the liver lesions between 1d prior to first-course chemotherapy and 1d prior to second-course chemotherapy were compared between responders and non-responders of the two groups, respectively. Results: The percentage change of lesion quantitative parameter peak intensity (PI) was statistically different (P=0.03), but that of all other parameters showed no statistical difference between responders and nonresponders in bevacizumab plus mFOLFOX6 treatment group (all P>0.05); no statistical difference was noted in percentage change of lesion quantitative parameters between responders and non-responders in mFOLFOX6 alone treatment group (all P>0.05). Conclusion: CEUS quantitative parameter PI has certain application value in evaluation of early response of colorectal cancer liver metastasis to bevacizumab plus cytotoxic chemotherapy.